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Subunit vaccines that use the vaccinia virus extracellular envelope protein A33R alone or combined with other structural proteins are excellent
candidates for a new smallpox vaccine. Since a new smallpox vaccine would be used in humans, who are the natural hosts for the Orthopoxvirus
variola, the agent of smallpox, it would be important to determine whether a prospective smallpox vaccine can protect from a lethal Orthopoxvirus
infection in a natural host. We addressed this question using the mouse-specific Orthopoxvirus ectromelia virus. We demonstrate that
immunization with recombinant ectromelia virus envelope protein EVM135 or its ortholog vaccinia virus A33R produced in E. coli protects
susceptible mice from a lethal ectromelia virus infection. This is the first report that a subunit vaccine can provide protection to a lethal
Orthopoxvirus infection in its natural host.
D 2005 Elsevier Inc. All rights reserved.Keywords: Rodent; Viral; Immunization; Poxvirus; Vaccinia virus; Ectromelia virus; Smallpox; Subunit vaccineIntroduction
Smallpox, an epidemic disease that decimated human
populations periodically throughout history, was caused by
variola virus (VARV), an Orthopoxvirus (OPV). Fortunately,
smallpox was eradicated worldwide through immunization
(Fenner et al., 1988). However, there is great fear that VARV,
monkeypox virus (MPXV) or engineered forms of these
pathogens could be used as biological weapons (Henderson,
1999). The effect of such an attack would be devastating
because massive immunization against smallpox was discon-
tinued in 1978 and most of the human population is presently
not immune. Furthermore, in recent years, epidemics of human
MPXV have occurred sporadically in west and central Africa,
and a recent outbreak occurred in the Midwestern United States
(Cunha, 2004; DiGiulio and Eckburg, 2004; Hutin et al., 2001)0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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may be necessary. In addition, there is a theoretical risk that
OPVs prevalent in animal populations could cross the species
barrier and become human pathogens.
The vaccine used by the World Health Organization to
eradicate naturally occurring smallpox disease is live vaccinia
virus (VACV), another well-known OPV (Fenner et al., 1988).
All OPV are highly homologous at the DNA and protein level,
accounting for the cross-protection that infection with these
viruses induces (Goebel et al., 1990; Shchelkunov et al., 2001,
2002).
While immunization with live VACV provides excellent
protection against smallpox, it routinely causes a pustular skin
lesion, frequently induces lymphadenopathy and fever, and
occasionally results in life-threatening disease (Cono et al.,
2003; Fulginiti et al., 2003). Indeed, immunization with VACV
is not recommended for millions of people with immune
deficiencies, eczema, atopic dermatitis and heart disease, all of
whom are at an increased risk of severe complications.
Therefore, there is a need to develop a safer vaccine that,6) 231 – 243
www.e
M. Fang et al. / Virology 345 (2006) 231–243232ideally, should be non-infectious but able to afford full
protection.
There are two forms of infectious OPV. The intracellular
mature virion (IMV) is infectious when released from
disrupted cells. It is resistant to the environment and thought
to be important in host-to-host transmission of the virus.
However, it induces antibodies that by themselves are not
protective. The extracellular enveloped virion (EEV), is
released from the infected cells. It is labile in the environment
and has an important role in dissemination of the virus within
the host. Importantly, it is the target of protective antibodies
(Appleyard et al., 1971; Blasco and Moss, 1992; Moss, 1996;
Payne, 1980; Smith et al., 2002). Unfortunately, killed VACV
induces antibodies but is not effective at preventing disease
because the killed virions are mostly IMV (Appleyard et al.,
1971; Galmiche et al., 1999; Payne, 1980; Payne and
Kristensson, 1985). Therefore, it has been proposed that a
new vaccine may include subunit vaccines based on
recombinant viral proteins important for virus spread and
pathogenesis. In support of this, Galmiche et al. (1999)
demonstrated that immunization with recombinant VACV
EEV proteins A33R or B5R produced in insect cells protected
mice from a lethal intra-nasal challenge with high-dose
VACV virus (107 plaque forming units, PFU). More recently,
Fogg et al. (2004) reported results of immunization with the
VACV EEV proteins A33R and B5R and the IMV L1R
produced in insect cells. They found that, when used
individually, A33R was more protective but that the combina-
tion of all three proteins was the most effective. In related
experiments, Hooper et al. (2004) found that DNA vaccines
consisting of cloned MPXV EEV genes A33R, B5R and IMV
L1R and A27L, protected rhesus macaques from high dose
intravenous (i.v.) challenge with MPXV. While these are
important developments towards a new vaccine, an important
caveat is that mice are not the natural hosts of VACV nor are
rhesus monkeys a natural host of MPXV, requiring high doses
of virus i.v. to initiate infection (Hooper et al., 2004) and
bypassing the natural mechanism of virus spread by producing
instant viremia (Earl et al., 2004). There are several reasons
why a prospective smallpox vaccine (a natural human disease)
should be tested in a natural host. First, viruses typically
replicate better in natural hosts and the immune mechanism
that may protect against a poorly replicating virus in non-
natural hosts may not be adequate to clear a virus that replicates
and spreads rapidly in a natural host. Second, vaccines must
protect individuals from transmission from host to host and
experiments of this type can only be performed in natural hosts.
Third, only with natural hosts can we evaluate protection to a
virus entering through the natural route and spreading as during
the normal course of the infection. Fourth, while the ultimate
goal of these studies is to develop a novel smallpox vaccine, for
obvious ethical reasons, such a vaccine cannot be tested in
humans; thus, experiments with similar viruses in natural hosts
combined with results of experiments in non-human primates
with MPXV (which are not natural pathogens of monkeys but
of wild rodents) may collectively provide the best possible
surrogates to predict protection from smallpox.While its evolutionary host is not known, the OPV
ectromelia virus (ECTV) can be considered a natural
pathogen of the laboratory mouse (Mus musculus) because
in this species it can complete its life cycle and be
perpetuated. In fact, the mouse is the only known natural
host of ECTV (Fenner, 1994). While all outbred and inbred
strains of laboratory mice can be infected with ECTV by any
route, footpad infection of susceptible strains causes mouse-
pox and can be lethal at very low doses only in susceptible
strains such as A/J and Balb/c. For example, as few as 3
(plaque forming units (PFU) of the Moscow strain of ECTV
injected in the footpad was 100% lethal to A/J male mice
(Chen et al., 1992). In our own experiments, 80–100% of
Balb/c mice succumbed and 100% developed mousepox
following footpad inoculation with 3  103 PFU ECTV
Moscow. Furthermore, introducing an infected mouse into a
cage of uninfected susceptible mice results in natural
transmission with 100% incidence of mousepox with high
lethality (Fenner, 1994; Niemialtowski et al., 1994).
Because ECTV infection of the mouse is a good model
for VARV or MPVX infection in humans, we tested
whether mice can be protected from mousepox and death
by immunization with a single recombinant EEV protein.
Our interest was to test a protein produced in bacteria
because it is a very efficient and economical method to
generate recombinant proteins. Since immunization with
insect-produced A33R is the most effective in protecting
mice from lethal VACV infection (Fogg et al., 2004;
Galmiche et al., 1999), we produced and tested ECTV
EVM135 (the ECTV ortholog of VACV A33R, 90.27%
amino acid identity) expressed in E. coli as a vaccine
against ECTV. In addition, to test whether well-conserved
OPV orthologs can be cross-protective, we also produced
and tested as a mousepox vaccine recombinant VACV
A33R. The results presented here demonstrate that both
proteins provide a high degree of protection against death,
but not against disease. Our work provides insight for the
development of a safer recombinant vaccine to OPV
infections in their natural host, which should be useful
for the development of new and safer vaccines against
smallpox and MPXV.
Results
Cloning, expression and purification of recombinant ECTV
EVM135
The coding sequence of the extraviral domains of ECTV
EVM135 with a His-Tag at the N terminus was cloned into the
expression vector pET-28a(+) to generate pET/EVM135 (Fig.
1A) which was used to produce recombinant EVM135 in E.
coli. As shown in Fig. 1B, SDS-PAGE and Coomassie brilliant
blue revealed a strong band with the expected molecular size
for recombinant EVM135 in inclusion bodies but not in the
supernatants of E. coli induced with IPTG. The band was
excised and partially sequenced by Edman degradation,
confirming its identity. The inclusion bodies containing EVM
Fig. 1. Cloning, expression and purification of ECTV EVM135. (A) Scheme of the expression vector. The extraviral domains of ECTV EVM135 (Moscow) was
amplified by PCR and cloned into pET-28a(+) to yield constructs pET/EVM135. An N-terminal histidine tail was added to facilitate protein purification. (B)
Expression of EVM135 in BL21(DE3) cells induced with IPTG. Lane 1: lysate of cells transformed with pET-28a(+). Lane 2: lysates of cells transformed with pET/
EVM135. Lane 3: as lane 2 but only the supernatant. Lane 4: as Lane 2 but only the pellet. Lane 5: molecular weight standards. (C) Purification of ECTV EVM135.
Lane 1: molecular weight standards. Lane 2: the inclusion bodies before purification. Lane 3: column flow through. Lane 4: purified ECTV EVM135.
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purified under denaturing conditions by chromatography using
Ni-NTA agarose columns (Fig. 1C) and refolded by dialysis
over PBS.
Characterization of recombinant EVM135
The production of recombinant proteins in bacteria is
simpler and more economical than in insect cells. However,
there is the caveat that normally glycosylated proteins may
not fold properly when expressed in bacteria. Because
EVM135 is normally glycosylated, we determined whether
our recombinant EVM135 produced in E. coli was properly
folded. We recorded far-UV circular dichroism (CD) spectra
in the absence and presence of DTT and guanidinium
chloride (GuCl) as denaturants. As shown in Fig. 2A, the
spectrum of the recombinant EVM135 in PBS exhibited a
strong negative band around 200 nm and a minor shoulder
around 222 nm. Assuming a molar mean-residue ellipticity
of 34,100 mdeg cm2 dmol1 for a fully a-helical peptide
(Scholtz and Baldwin, 1992), the data indicate that recom-
binant EVM135 has secondary structure with at least 10% a-
helix content. Few changes were observed in the spectra
following addition of 1 mM DTT indicating that EVM135
has a compact structure that is very stable in solution. When
5.9 M GuCl, was added, the spectra with or without DTT
showed that all the features of the spectra compatible with a
secondary structure were lost indicating that under these
harsh conditions, recombinant EVM135 unfolds. Together,
the CD data indicates that recombinant EVM135 is folded in
solution.
VACV A33R protein and most likely its orthologs (includ-
ing EVM135) are glycosylated transmembrane proteins thatform dimers joined by disulfide-bonds (Roper et al., 1996). It
was therefore important to determine the oligomeric state of
recombinant EVM135. Size exclusion gel filtration analysis of
the thawed protein stock revealed a major peak with an
apparent molecular weight corresponding to that of dimers
(peak 2 in Fig. 2B). An additional minor peak detected as a
faster eluting shoulder was also apparent (peak 1, Fig. 2B).
This seemed to indicate the presence of some contaminating
aggregates in the protein stock. Peak 2 was purified by gel
filtration and analyzed by light scattering, which allows for the
precise determination of the hydrodynamic radius and size of a
molecule in solution. As shown in the lower panel of Fig. 2C,
the scattering intensity distribution of the purified peak 2 gave
a single peak, suggesting the absence of aggregation. The
hydrodynamic radius of the protein was 31.9 A˚ and the
molecular weight was 27.7 kDa as determined by dynamic
light scattering (DLS) and static light scattering (SLS),
respectively. This confirmed the gel filtration data indicating
that the major component of EVM135 in our stock forms
dimers in solution.
EVM135 and A33R are natural targets of the anti-OPV
antibody response
To determine whether ECTV EVM135 and its VACV
ortholog A33R are natural targets of the anti-OPV antibody
response and whether they are cross-reactive, we produced
VACVA33R exactly as described for EVM135. ELISA plates
were coated with the recombinant proteins and tested for
recognition by anti-ECTVor anti-VACVantisera obtained from
mice that had been infected 8 weeks earlier. As shown in Figs.
3A and B, anti-ECTV and anti-VACV antisera recognized both
recombinant proteins. However, the cross-reactivity was not
Fig. 2. Recombinant EVM135 is folded and forms dimers in solution. (A) Far-UV circular dichroism spectra was recorded in the absence and presence of DTT and
GuCl as denaturants as indicated. (B) Gel filtration separation and analysis of EVM135. The protein shows a major peak at elution volume of about 15 ml consistent
with the size of dimers. (C) Dynamic light scattering spectra of peak fraction (2). The hydrodynamic radius of the protein measured by dynamic light scattering
(DLS) was 31.9 A˚ and the molecular weight was 27.7 kDa as determined by static light scattering (SLS) confirming that the protein forms dimers in solution. The
upper panel is the measured correlation function (O). The solid line is the regularization fit to the correlation function. Middle panel is the sum-of-squares differences
between the experimental measured autocorrelation function and the fit. Lower panel is Laplace transformation of the regularization fit. A single peak indicates the
absence of aggregation.
Fig. 3. EVM135 and A33R are natural targets of the anti-OPV antibody response. 96-well bottom ELISA plates were coated with purified recombinant EVM135,
A33R or lysates of ECTV, VACVor LCMV-infected cells as indicated. The indicated antisera were collected from ECTV, VACVor LCMV infected mice 8 weeks pi.
(A) Reactivity of ECTV-immunized serum with different antigens. (B) Reactivity of VACV-immunized serum with different antigens. (C) Reactivity of LCMV-
immunized serum with different antigens. (D) Reactivity of naive serum with different antigens.
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protein better. As expected, both antisera recognized control
VACV or ECTV-coated plates (Figs. 3A and B). Additional
controls confirmed that the ELISA assays were specific
because the anti-ECTV or anti-VACV antisera did not react
with ELISA plates coated with lysates of LCMV-infected cells
(Figs. 3A and B) while anti-LCMVantisera reacted with plates
covered with LCMV lysates but not with any of the OPV
antigens (Fig. 3C). Moreover, sera from naive mice did not
react with any of the antigens (Fig. 3D). Together, these data
indicate that EVM135 and A33R are natural targets of the anti-
ECTV and anti-VACV antibody responses and that the elicited
antibodies are cross-reactive with the heterologous protein. In
addition, the data show that the recombinant EVM135 and
A33R maintain at least some of the epitopes of the natural
proteins produced during infection.Fig. 4. Immunization with recombinant EVM135 or A33R elicits strong antibody res
coated with purified recombinant EVM135 (A) or A33R (B) 5 both at 5 Ag/well.
antibodies were detected using anti-mouse immunoglobulin G (IgG) (g chain specifi
were infected with 60 PFU ECTV. After 1 h, the media was replaced with fresh medi
days later, the supernatant was aspirated and the monolayers were fixed and staineImmunization with EVM135 or A33R elicit antibody responses
in mice
To determine whether recombinant EVM135 or A33R can
elicit antibody responses in mice, groups of 10 mice were
immunized twice in the base of the tail with incomplete
Freund adjuvant (IFA) admixed with 10 Ag EVM135 (IFA-
EVM135) or A33R (IFA-A33R) in PBS or only with PBS
(IFA-PBS) as negative control. The presence of specific
antibodies before immunization and 3 weeks after the second
immunization was determined in sera by ELISA. The results
using pooled sera from 10 mice shows that immunization with
EVM135 and A33R elicited strong IgG responses , which
seemed to be partially cross-reactive as detected by ELISA in
which plated EVM-135 was recognized 3-fold better by anti-
EVM135 antisera (Fig. 4A) and A33R was recognized 3-ponses that are functional in vitro. (A and B) 96-well bottom ELISA plates were
Serum was collected from EVM135- or A33R-immunized mice. Specific IgG
c) peroxidase-conjugated antibody. (C). BSC-1 cell monolayers in 6 well plates
a containing the indicated dilutions of the anti-EVM135 or ECTVantisera. Five
d with crystal violet.
Fig. 5. Immunization with recombinant EVM135 or VACV A33R protects
susceptible mice from lethal ECTV infection. BALB/c mice were immunized
twice with IFA-EVM135, IFA-A33R or IFA-PBS or once with VACV. Three
weeks after the last immunization, mice were infected with 3  103 PFU ECTV
in the footpad. (A) Kaplan–Meier survival curves following ECTV challenge
of immunized and mock-immunized mice. Log-rank test demonstrated a
significant difference between the IFA-EVM 135 and IFA-PBS groups (P =
0.0001) and also between the IFA-A33R and IFA-PBS (P = 0.0001). There was
no significant difference between the IFA-EVM-135 and IFA-A33R groups
(P = 0.7401). The difference between both groups immunized with recombinant
protein compared with mice immunized with VACVwas significant (P = 0.012).
(B) Weight change following ECTV challenge. Accumulated data for
three experiments with a total of 30 mice/treatment. Data points indicate
means T SE.
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was further confirmed in limiting-dilution experiments where
titers were determined by ELISA using sera from three
individual mice immunized with EVM135. In this case the
antibody titers expressed in Log10 were 5.66 T 0.16 when
EVM135 was on the plate, and 4.39 T 0 when A33R was the
coating antigen. Conversely, sera from three individual mice
immunized with A33R reacted somewhat better with A33R
than with EVM135 (end-point titers of 5.5 T 0.16 and 4. 5 T
0.16, respectively). In both cases the P value in two-tailed t
test was <0.00002. This demonstrates that the cross-reactivity
between the two proteins was not complete, probably due to
the presence of public and private epitopes. As mentioned
above, EEVs are responsible for the in vivo long-range
dissemination of OPVs. For OPV isolates that produce large
numbers of EEV such as the VACV strain IHD-J, this is
mimicked by the appearance of comet-shaped plaques in
infected cultured cell monolayers with liquid overlays. These
comets are formed by a single primary plaque that represents
the head of the comet, and many secondary plaques that
represent the tail of the comet and result from the release of
EEVs from the primary plaque to the extracellular milieu and
the subsequent infection of other cells (Appleyard et al., 1971;
Vanderplasschen et al., 1997). It has been shown that when
antibodies to EEV or the EEV proteins B5R or A33R are
added to the liquid overlay of recently infected cell mono-
layers, the release of EEV to the media is blocked, the
formation of comets is inhibited and the plaques take a
rounded appearance. Therefore, inhibition of comet formation
is indicative of biological activity of the antibody (Appleyard
et al., 1971; Fogg et al., 2004; Galmiche et al., 1999;
Vanderplasschen et al., 1997). In our experience, the Moscow
strain of ECTV also forms comets. Therefore, we determined
whether comet formation by ECTV could be inhibited with
antisera to EVM135 or, as a positive control, to ECTV. Fig. 4C
shows that, anti ECTV antisera could inhibit comet formation
even at a dilution of 1/5000. Anti-EVM135 antisera was also
able to completely inhibit comet formation although, as
reported for anti-A33R (Galmiche et al., 1999), only at high
concentrations. Therefore, anti-EVM135 antisera produced by
immunization with a recombinant protein produced in bacteria
shows functional activity in vitro.
Recombinant EVM135 and A33R protect susceptible mice from
lethal ECTV infection
To test whether immunization can protect susceptible mice
from footpad ECTV infection, we immunized groups of
mousepox-sensitive Balb/c mice twice with IFA-EVM135,
IFA-A33R or IFA-PBS and 3 weeks later we challenged them
with 3,000 PFU ECTV in the footpad. As a positive control for
protection, we included a group of mice that had been infected
with VACV 3weeks earlier. To evaluate protection from disease,
we observed the mice for the characteristic signs of mousepox
and determined their weight over a period of 6 weeks pi.
Moribund mice (unresponsiveness to touch, lack of voluntary
movements) were euthanized and counted as dead. Threeindependent experiments, each with 10 mice per group, were
performed. The data for the combined experiments are shown in
Fig. 5. Only 2 (less than 7%) mice in the IFA-PBS group
survived past 2 weeks pi (Fig. 5A) and the two surviving mice
developed rash and experienced a severe weight loss that peaked
13 days pi (Fig. 5B). As expected, all mice immunized with
VACV survived and did not experience any weight loss. Most
important for this work, mice immunized with any of the
recombinant proteins were equally and significantly protected
from death (P = 0.0001, Fig. 5A) with 70% of the mice
immunized with EVM135 (21 mice) and 73% of those
immunized with A33R (22 mice) surviving. Still, immunization
with the recombinant proteins was not as effective in protecting
mice as VACV immunization because mice immunized with
either EVM135 or A33R were significantly less protected from
death, and developed mousepox and experienced substantial
weight loss (Fig. 5B). However, the signs of mousepox and
weight loss were not as pronounced as those of the two sur-
viving IFA-PBS controls and their recovery was faster. There-
fore, immunization with recombinant EVM135 or A33R can
protect against death but not against disease following infection
with an OPV in a natural host under our experimental
conditions.
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naturally transmitted ECTV infection
The results above demonstrate that immunization with
recombinant EVM135 or A33R can protect mice from lethal
experimental inoculation with ECTV. However, it is also of
interest to determine to what extent immunization can protect
from a naturally transmitted infection and independent of the
experimental virus dose. Therefore, naive mice were infected
with ECTV and immediately introduced into cages containing
uninfected mice that had been immunized with IFA-EVM135,
IFA-A33R or IFA-PBS. As shown in Table 1, all mice
immunized with IFA-EVM135 or IFA-A33R developed
mousepox but survived the infection. On the other hand, all
the mice in the IFA-PBS group developed severe mousepox
and 50% died 14–20 days after introducing the infected mice.
Therefore, immunization with EVM135 or A33R can also
protect from death but not disease when ECTV is transmitted
naturally.
Reduced virus loads in organs of EVM135- and
A33R-immunized mice after ECTV infection
The results above suggested that mice immunized with
IFA-EVM135 or IFA-A33R controlled the virus better than
mice inoculated with IFA-PBS but less well than mice that
received VACV. To confirm that this was the case, we
compared virus titers in spleen and liver of the different
groups 7 days pi. The results in Fig. 6A show that
immunization with EVM135 or A33R resulted in a 20-
fold reduction of virus titers in spleen and 104 reduction in
liver as compared with the PBS-immunized group. These
differences in virus titers between immunized and mock-
immunized mice were statistically significant. Because death
from mousepox is due to massive liver necrosis as a
consequence of uncontrolled virus replication, the reduced
virus loads in liver of mice immunized with EVM135 or
A33R may account for the decreased mortality. Consistent
with the absence of morbidity, immunization with VACV
resulted in even lower virus titers in spleens and livers
(i.e., more than 105 lower than in mice immunized with
IFA-PBS).Table 1
Immunization with EVM135 or A33R partially protect against natural ECTV
infection
Immunization PBS EVM135
or A33R
Mousepox/total 10/10 10/10
Death/total 5/10 0/10
Day of deatha 14–20 NA
Naive mice were infected with ECTVand immediately introduced into cages of
uninfected mice that had been vaccinated with IFA-EVM135, IFA-A33R or
IFA-PBS.
a After introduction of infected mice. All groups consisted of 10 mice. NA:
not applicable.Mice immunized with EVM135 and A33R have higher number
of lymphocytes and antigen-specific CD8+ T cells in their
spleens following ECTV infection
The reports mentioned above where subunit vaccines were
tested for protection against VACV in mice or MPXV in
monkeys looked at antibody responses but not at T cell
responses (Fogg et al., 2004; Galmiche et al., 1999; Hooper et
al., 2003). However, the CD8+ T cell response is known to be
important for protection against primary OPV infections
including VACV and ECTV (Blanden, 1970; Blanden,
1971b; Buller et al., 1987; Fenner et al., 1988; Karupiah et
al., 1996). Therefore, we thought it was important to determine
whether immunization with EVM135 could have any affect on
the T cell response after virus challenge. Mice immunized with
recombinant EVM135, A33R, mock-immunized mice and
mice immunized with VACV were challenged with ECTV in
the footpad and 7 days later, their spleens were collected. The
total number of splenocytes of IFA-EVM135 (2.2 T 0.3  108)
and IFA-A33R mice (2.1 T 0.5  108) increased, but not
significantly in respect to uninfected controls (1.5 T 0.05 
108) while IFA-PBS mice experienced a sharp three-fold
decrease (0.58 T 0.2  108) which was statistically significant
(Fig. 7A). Moreover, while IFA-EVM135, IFA-A33R and IFA-
PBS mice had a decrease in the percentages of CD8+ T cells
(Fig. 7B), this reduction was much more severe in IFA-PBS
mice. This resulted in almost 10-fold reduction in the absolute
number of CD8+ T cells in the spleens of IFA-PBS mice (Fig.
7D). Therefore, while the relative numbers of virus-specific
CD8+ T cells in immunized and mock-immunized mice were
similar as determined by intracellular granzyme B (GzB) and
IFN-g staining following 6 h in vitro restimulation with VACV-
infected cells (Fig. 7C), the absolute numbers of virus-specific
CD8+ T cells in the spleens of IFA-EVM135 (1.83 T 0.2  106)
and IFA-A33R (1.85 T 0.5  106) were much higher than in
IFA-PBS mice (0.24 T 0.1  106) (Fig. 7E). This decrease in
the cell content in the spleens of mock-immunized mice is due
to necrosis as a result of the infection (Blanden, 1971a; Fenner,
1994). Therefore, the reduced virus burden in mice immunized
with the recombinant proteins seems to prevent lymphocyte
depopulation of the spleens, resulting in very increased number
of antigen-specific CD8+ T cells that may substantially
contribute to their survival. Of note, proportionally fewer
IFN-g or GzB producing cells were found in the spleens of
VACV-immunized mice. This is consistent with our finding
that most of the T cell response against footpad ECTV in
VACV-immunized mice occurs in the draining lymph node and
not in the spleen (unpublished observations).
Discussion
Little is known about the mechanism by which immuniza-
tion with VACV virus confers protection against OPV
infections. Several lines of evidence, primarily natural experi-
ments involving smallpox patients with underlying defects of
the immune system, indicate that both the humoral and cell-
mediated arms of the immune system play important roles in
FIG. 6. Immunization with recombinant EVM135 and A33R decreases virus loads in spleen and liver after ECTV challenge. Groups of five Balb/c mice were
immunized twice with IFA-EVM135, IFA-A33R or IFA-PBS or once with VACV virus. Three weeks following the last immunization, mice were infected with 3,000
PFU ECTV in the footpad. Seven days pi, mice were euthanized and virus titers were determined. (A) Virus titers in spleens. Two tailed t tests demonstrated
significant differences in virus titers between mice immunized with IFA-PBS and IFA-A33R (P = 0.003), IFA-EVM135 (P = 0.01) or VACV (P = 0.0004). (B) Virus
titers in liver. Two tailed t test demonstrated significant differences between mice immunized with IFA-PBS and IFA-A33R (P = 0.007), IFA-EVM135 (P = 0.001) or
VACV ( P = 0.002). DL, detection limit.
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(2003) reported that antibodies were necessary for protection
against VACV induced disease in vaccinated mice whereas
CD4+ and CD8+ T cells were neither necessary nor sufficient.
In addition, they showed that the CD4+ and CD8+ T cell
responses could protect from VACV death in the absence of
antibody (Belyakov et al., 2003). In our own studies, many
immunodeficient mice such as TAP, B cell or CD40-deficient
mice can control VACV infection (5  106 PFU/mouse, i.p.)
with no adverse effects (unpublished results). However, survival
from primary ECTV infection requires antibodies, CD4+ and
CD8+ T cells (Fang and Sigal, in press). Furthermore,
immunization with VACV virus cannot protect mice from
ECTV infection in the absence of antibodies (Fang and Sigal,
unpublished observations). This indicates that the requirements
for the control of ECTV are much more stringent even though
VACV and ECTV are very related. Therefore, it is important to
confirm results of protective immunization against VACV in an
animal model with a natural pathogen such as ECTV.
In this paper, we produced recombinant ECTV EVM135
and its ortholog VACVA33R in E. coli. Characterization of the
recombinant proteins showed that they fold in stable structures
and form dimers, which is the dominant form of the natural
proteins (Roper et al., 1996). When we used the recombinant
proteins as probes, we found that both were recognized by anti-
ECTVor anti-VACVantisera but each was better recognized by
antisera to the homologous virus. This indicates that EVM135
and A33R are natural targets of the antibody responses during
ECTV and VACV infections and, as expected from their
sequence homology, that they are partially cross-reactive.
Importantly, these data also indicate that antibodies produced
during natural ECTV and VACV infections recognize recom-
binant EVM135 and A33R produced in E. coli. Therefore,
while we do not know whether all natural epitopes of the
EVM135 and A33R are conserved in the recombinant proteins,
it is clear that at least some are retained and this may be
important for protection.Immunization of mice with recombinant EVM135 or A33R
elicited strong IgG antibody responses that were also partially
cross-reactive. Despite the incomplete cross-reactivity, immu-
nization with either protein protected 70% of susceptible
BALB/c mice from death following ECTV footpad infection.
Moreover, 100% of the immunized mice survived infection by
natural transmission, an experiment that can only be accom-
plished with a natural pathogen such as ECTV in mice. The
reason why the level of protection achieved with both proteins
was similar while the antibody cross-reactivity was only partial
is not resolved by our data. However, a lack of correlation
between antibody titer and degree of protection was also
observed by others that looked for protection to VACV
infection (Galmiche et al., 1999). Among others, possible
reasons to account for similar protection without complete
cross-reactivity may be that protection is dependent on specific
epitopes shared between the two proteins or that protection is
mediated by T cells cross-reactive between the two proteins.
All mice immunized with recombinant EVM135 or A33R
developed mousepox after ECTV inoculation or natural
transmission. Therefore, immunization with the recombinant
proteins provided significant protection from death but not
from disease. This was different from mice immunized with
VACV, which remained healthy. The outcome of the different
immunizations in terms of protection is consistent with the
virus titers after challenge. Thus, mock-immunized mice had
107–108 PFU of virus in spleen and liver, mice immunized
with the recombinant proteins had a 20-fold reduction in
virus loads in spleen and 104-fold drop in liver, and VACV-
immunized mice had more than 105 decrease in both organs.
Recently, Fogg et al. (2004) reported that among several
recombinant proteins produced in insect cells, immunization
with A33R was the most effective in protecting from intranasal
inoculation with 106 PFU VACV. However, protection was not
complete and the animals experienced weight loss similar to
our results. Therefore, production of OPV proteins in E. coli
may be a good alternative to insect cells to produce
Fig. 7. Immunization with recombinant EVM135 or A33R protect the spleen from ECTV-induced lymphocyte depletion resulting in a larger number of antigen-
specific T cells. Groups of five mice were immunized with IFA-EVM135, IFA-A33R or IFA-PBS twice or VACV once. Three weeks after the last immunization,
mice were challenged with ECTV. One week pi mice were euthanized and spleen cells analyzed by flow cytometry. (A) Total lymphocytes per spleen in different
groups as determined by counting live cells at the microscope by trypan blue exclusion. The difference in total lymphocytes between IFA-PBS and the naive control
was statistically significant (P = 0.008). (B) Flow cytometry analysis showing the proportion of CD8+ T cells in the spleen. FSA: forward scatter amplitude. Stains as
indicated. (C) Flow cytometry analysis showing antigen-specific CD8+ T cell responses. Graphs are gated on CD8+ T cells. Numbers indicate the proportion of CD8+
T cells in the nearest quadrant. Stains as indicated. (D) Total number of CD8+ T cells per spleen in different groups calculated from A and B. The difference in total
CD8+ T cells between IFA-PBS and the naive control was statistically significant in two tailed t tests (P = 0.0001). (E) Antigen-specific CD8+ T cells per spleen in
different groups calculated from D and C. Two tailed t tests demonstrated significant differences in the absolute numbers of antigen-specific CD8+ T cells between
mice immunized with IFA-PBS and IFA-A33R (P = 0.01), IFA-EVM135 (P = 0.001) or VACV (P = 0.002).
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reported improved protection by combining A33R together
with B5R and/or the IMV protein L1 also produced in insect
cell. It will therefore be interesting to determine whether these
or other combinations of recombinant proteins produced in E.
coli can afford complete protection from mousepox and
compare with those produced in insect cells.
None of the previous reports that tested subunit vaccines in
different models of OPV infections analyzed the effect of
immunization on the T cell responses (Fogg et al., 2004;
Galmiche et al., 1999; Hooper et al., 2004). However, it has been
reported by Galmiche et al. (1999) that mice immunized with
recombinant B5R were protected against a lethal VACV
challenge, and the protection was most likely mediated by
neutralizing antibodies. A33R was also protective in active and
passive immunization, but in contrast to B5R, protection with
A33R did not correlate with antibody titers in serum (Galmiche
et al., 1999). In addition, because anti-A33R antibodies did not
neutralize EEV in vitro (Galmiche et al., 1999), it was proposed
that the protection mediated by A33R might partly involve a
mechanism different from antibody neutralization such as
complement-mediated lysis (Lustig et al., 2004) or T cell
responses. Because T cell responses are known to be important
in protection against primary ECTV infections, we tested
whether EVM135 or A33R-immunized mice generated stronger
T cell responses than mock-immunized mice following ECTV
challenge. Interestingly, we found that the proportion of CD8+ T
cells that produced IFN-g and GzB was not markedly different
between the immunized and mock-immunized group. However,
the total number of antigen-specific CD8+ Tcells in the spleen of
mice immunized with EVM135 or A33R was increased 10-fold
due to a slight increase as opposed to a sharp decrease in the total
number of lymphocyte in the spleen after infection. The
depletion of lymphocytes in mock-immunized mice is likely
due to the necrosis of the spleen due to the infection (Fenner,
1994). The mechanism of protection form lymphocyte depletion
in the immunized groups is still unknown. In our view, the most
likely explanation is that the presence of anti-EVM135/A33R
antibodies delays the spread and/or replication of ECTV
sufficiently to allow for the development of a strong cellular
response, which is essential for protection even in the presence
of antibodies (submitted). Alternatively, vaccination may induce
EVM135/A33R-specific CD8+ T cell responses through cross-
priming (Norbury and Sigal, 2003), a mechanism whereby
professional antigen presenting cells can present exogenous
antigens with their own MHC class I molecules. In this regard,
we have found that naive Balb/c mice can be protected from
disease and death following ECTV challenge when adoptively
transferred with memory CD8+ T cells from VACV-immunized
mice (submitted). Adoptive transfer experiments with CD8+ T
cells from mice immunized with EVM135/A33R are unlikely to
succeed because the number of memory cells should be much
lower than following VACV immunization. While for technical
reasons, we have been unable to directly determine whether
CD8+ T cells specific for EVM135/A33R are induced by
vaccination, based on our own experience immunizing with
other non-replicating antigens such as chicken ovalbumin, wethink it is improbable that all the virus-specific CD8+ Tcells that
we detect 7 days pi are directed to EVM135/A33R. More likely,
a secondary response of a low number of memory CD8+ T cells
resulting from the vaccination could aid the primary response of
CD8+ T cells of other specificities (submitted). Unfortunately,
this hypothesis cannot be tested at the present time. While CD8+
T cell epitopes shared between ECTV and VACV have been
found for the C57BL/6 mouse (H-2b) (Tscharke et al., 2005),
none have yet been described for the Balb/c background (H-2d).
In any case, the overall increase in antigen-specific CD8+ Tcells
resulting from the immunization with EVM135 or A33R is
likely to be crucial for the improved survival of the immunized
mice.
In summary, our work demonstrates that immunization with
recombinant EVM135 or its VACV ortholog can protect a
natural host from a lethal OPV infection following experimental
inoculation or natural transmission. While this protection is
partial and much less effective than that induced by VACV
immunization, our results are promising because they showed
for the first time that a single recombinant EEV protein
produced in E. coli can be used to protect against a lethal
OPV infection in its natural host. To achieve complete
protection, EVM135 could be combined with other EEV or
IMV proteins or secreted proteins involved in pathogenesis such
as mimics of cytokines and chemokines receptors that are used
by the virus to evade the immune response (Alcami and
Koszinowski, 2000; Alcami and Smith, 1996; Smith et al.,
1999). Testing these and other proteins in protection from
mousepox will provide a very valuable model for a safer subunit
vaccine to smallpox and other OPV infections in humans.
Materials and methods
Cells
HeLa S3, A20 and BSC-1 cells were obtained from ATCC.
As standard tissue culture media, we used RPMI 10 that
consisted of RPMI 1640 tissue culture media (Invitrogen)
supplemented with 10% fetal calf serum (Sigma), 100 IU/ml
penicillin and 100 Ag/ml streptomycin (Invitrogen), 10 mM
Hepes buffer (Invitrogen) and 0.05 mM 2-mercaptoethanol
(Sigma). When indicated, RPMI 2.5 (as above but with 2.5%
FCS) was used instead. When required, 10 U/ml interleukin 2
(IL-2) was added to RPMI 10 (RPMI 10-IL2). All cells were
grown at 37 -C and 5% CO2.
Viruses
Initial stocks of VACV Western Reserve were obtained from
Dr. Bernard Moss (National Institute of Allergy and Infectious
Diseases, Bethesda, MD) and amplified in HeLa S3 cells as
described (Elroy-Stein and Moss, 1992). Briefly, HeLa S3 cells
in T150 flasks were infected with 0.1 PFU/cell VACV. After 3
or 4 days cells were collected, resuspended in PBS, frozen and
thawed three times, and stored in aliquots at 80 -C as virus
stock. Virus titers in VACV stocks were determined by plaque
assays on confluent BSC-1 cells using 10-fold serial dilutions
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dilution) for 1 h. 2 ml fresh RPMI 2.5 was added and the cells
incubated at 37 -C for 3 days (VACV). Next, the media was
aspirated and the cells fixed and stained for 10 min with 0.1%
crystal violet in 20% ethanol. The fix/stain solution was
subsequently aspirated, the cells air-dried, the plaques counted,
and the PFU/ml in stocks were calculated accordingly.
Initial stocks of ECTV Moscow (Chen et al., 1992; Fenner,
1949) were obtained from ATCC (#VR-1374). New stocks were
expanded by infecting BALB/c mice with 3,000 PFU of ECTV
in the footpad. Seven days post-infection, the spleen and liver
were removed and homogenized using a tissue homogenizer.
The solid material was pelleted by centrifugation and the super-
natant was stored in aliquots at 80 -C as virus stock. Titers in
stocks were determined as for VACV but the plates were incu-
bated for 5 days. For the determination of virus titers in spleens,
the organs were removed from experimental mice 7 days after
footpad infection, made into a single cell suspension between
two frosted slides and resuspended in 10 ml complete RPMI
medium. 1 ml of the cell suspensions were frozen and thawed
three times and titers determined in 10-fold serial dilutions of the
cell lysates as above. Virus titers were calculated as PFU/spleen.
To determine the virus titers in liver, a portion of the liver was
weighed and homogenized in medium using a tissue homoge-
nizer. The virus titers were calculated as PFU/100 mg liver.
Stocks of lymphocytic choriomeningitis virus strain Armstrong
were a kind gift of Dr. Glenn Rall (Fox Chase Cancer Center).
Production and characterization of recombinant EVM135 and
A33R
The coding sequences for the extraviral domains of ECTV
Moscow EVM135 and VACV Western Reserve A33R (Gal-
miche et al., 1999; Roper et al., 1996) were amplified by PCR
from genomic DNA. To facilitate purification, the recombinant
proteins were designed to contain a terminal 6  His tag.
Because VACV A33R and its orthologs such as ECTV
EVM135 are type II proteins (Roper et al., 1996), their C-
termini are exposed at the surface of EEV. Therefore, the 6 
His tag was fused to the N-terminus. For EVM135, we used
5 VAAACCATGGGCCATCACCATCACCATCACTGC-
AAACCATGGGCCATCACCATCACCATCACTGC-
ATGTCTGCTAACGAGGTTG and 5V AAACTCGAGTTAGQ
TTCATTATTTTAACACAAAAATACTTTC as the forward
and reverse primers respectively. For A33R the forward and
reverse primers used were 5VAAACCATGGGCCATCACCATQ
CACCATCACTGCATGTCTGCTAACGAGGCTG and
AAACTCGAGTTAGTTCATTGTTTTAACACAAAAATAC-
TTTC respectivelyThe amplified products were cloned into
pET-28a(+) vector and transformed into DH5a competent cells.
The expression vector was verified by DNA sequencing and
then transformed into BL21(DE3) competent cells for expres-
sion. The transformed BL21(DE3) cells were grown overnight
at 37 -C and inoculated at 5% into LB medium. The culture was
grown at 37 -C until the A600 was achieved. IPTG (final
concentration 0.4 mM) was added to induce protein expression
and cells were harvested 4h later and lysed by sonication. Theinclusion bodies were pelleted by centrifugation for 20 min at
8000  g, washed with washing buffer (20 mM Tris–HCl pH
8.0, containing 1% Triton-X100) followed by distilled water to
remove contaminating salts and detergents.
Recombinant EVM135 and A33R were purified under
denaturing conditions by Ni-NTA metal affinity chromatogra-
phy. The inclusion bodies were solubilized with 8M urea and
loaded onto Ni-NTA agarose (Qiagen), according to the
manufacturer’s recommendations. After washing out the
unbound proteins, the target protein was eluted by 0.5M
imidazole in 8M Urea lysis buffer. The purified proteins were
refolded by dialysis against PBS (phosphate-buffered saline).
Protein concentrations were determined using a bicinchoninic
acid assay (Pierce) with bovine serum albumin as a standard.
The purity of each protein was confirmed by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis. The same proteins
were used for characterization, immunization and ELISA.
Circular dichroism (CD) spectra were acquired at 20 -C on
an Aviv 62A spectropolarimeter (Aviv, Lakewood, NJ), in 1 mm
quartz cuvettes using 9.6 AMprotein in PBS. Each CD spectrum
is an average of five scans recorded in the far-UV region (190–
250 nm) with a band pass of 2 nm. The spectra in the presence
of DTT were obtained by adding concentrated 1 M DTT stock
solution to a final concentration of 1 mM. The spectra in the
presence of guanidium chloride (GuCl) were obtained by
dissolving the protein in 5.9 M GuCl solution. The spectra in
the presence of DTT and GuCl were only recorded from 210–
250 and 215–250 nm, respectively because at other wave-
lengths DTT and GuCl contribute heavily to the signal.
To determine the tertiary structure and the oligomeric state,
the recombinant EVM135 was size-analyzed by gel filtration
FPLC using a Superdex 200 10/30 column. The major peak
observed by gel filtration, which corresponded to the expected
size of EVM135 dimers, was collected and further analyzed by
light scattering at 10 -C on a DynaPro Molecular Sizing
Instrument with Dynamics V6 data analysis software (Protein
Solutions, Inc, NJ). This instrument has the capability of
conducting both static light scattering (SLS) and dynamic light
scattering (DLS) experiments simultaneously. SLS measures the
absolute molecular weight of the protein, while DLS measures
the hydrodynamic radius Rh and estimates the monodispersity of
the measured proteins (van Holde et al., 1998). Two concentra-
tions at 0.5 and 1.05 mg/ml were measured.
Production of antisera
Anti-virus antisera was produced by infecting C57BL/6
mice with ECTV (3,000 PFU in the footpad), VACV (5  106
PFU ip) or LCMV (3000 PFU ip). Eight weeks pi, mice were
anesthetized and exsanguinated from the orbital sinus. The
blood was allowed to clot, and the sera separated by
centrifugation. Antisera was stored in aliquots at 80 -C.
Immunization protocol
6- to 8-week-old female BALB/c mice bred at Fox Chase
were immunized subcutaneously (base of tail) two times with
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in Freund’s incomplete adjuvant (IFA). Preliminary experiments
showed that immunization of mice one or 2 weeks apart induced
similar levels of antibodies when measured 2 weeks after the
booster immunization (not shown). The 1-week interval was
chosen for all the experiments. For immunization with VACV, 6-
to 8-week-old female BALB/c mice were inoculated once
intraperitoneally with 0.5 ml PBS containing 5  106 PFU
VACV. Four weeks after the first injection or VACV infection,
the mice were challenged in the hind footpad with 3000 PFU of
ECTV. The mice were observed daily for disease and imminent
signs of death, and their body weights were monitored. The
amount of specific antibody contained in a blood sample taken
before challenge or at different time after challenge was
determined by ELISA. Animal protocols were approved by the
Institutional Animal Care and Use Committee (IACUC).
ELISA
96-well bottom ELISA plates were coated 4 -C overnight
with 0.1 ml of recombinant protein (50 Ag/ml) or lysates of
VACV virus-infected cell (2  107 PFU/ml), ECTV virus (2 
107 PFU/ml) or LCMV infected cell lysates, all in Na2HPO4–
NaHPO4 buffer, pH 9.0. Plates were blocked for 2 h at 37 -C
with PBS 1% BSA. Mouse sera were serially diluted in PBS
containing 0.5% BSA, 0.05% Tween-20, and 0.1 ml was added
to each well. The plates were then incubated for 1 h at 37 -C
and washed three times with PBS containing 0.05% Tween-20.
0.1 ml of peroxidase-conjugated affinity purified goat anti-
mouse IgG (g chain specific) or IgM (A chain specific) (both
from KPL) were added to each well at a dilution of 1:2,000,
incubated for 1 h at 37 -C, and then washed five times with
PBS containing 0.05% Tween-20. SureBlue TMB 1-Compo-
nent Microwell Peroxidase Substrate (KPL) was added to each
well (50 Al) and the plates were incubated at room temperature
for 5–20 min. The reactions were stopped by addition of 100
Al 0.12M HCl. The optical density (OD) at 450 nm was
determined using a microplate spectrophotometer (AQuant,
Bio-Tek).
Comet inhibition assay
Confluent BSC-1 cells in 6 well plates were infected with 60
pfu ECTV in 0.5 ml RPMI 2.5. After 1-h incubation at 37 -C,
the media containing virus was aspirated and the cells overlaid
with 1.5 ml RPMI 2.5 containing the indicated dilutions of
antisera. Cells were incubated for 5 days at 37 -C and stained
with crystal violet as described for virus titers.
Flow cytometry
Seven days after ECTV infection, mice were euthanized and
single-cell suspensions of each spleen were prepared in 10 ml
complete RPMI medium. Following osmotic lysis of red blood
cells with 0.84% NH4Cl, the spleen cells were washed, and 10
6
cells were stimulated for 6 h at 37 -C with 2  105 VACV-
infected or uninfected A20 cells in 96-well plates. Brefeldin A(BFA, Sigma) was added after 5 h to block the secretory
pathway and allow for the accumulation of cytokines inside the
cells. Following stimulation, antibody 2.4G2 (anti-Fcg II/III
receptor, ATCC) was added to block non-specific binding of
labelled antibodies to Fc receptors. The cells were then stained
for cell surface molecules, fixed, permeabilized, and stained for
intracellular molecules using the Cytofix/Cytoperm kit (Becton
Dickinson, BD) according to the manufacturer’s instructions.
The following antibodies were used: anti-CD8a (53–6.7, BD),
anti-IFN-g (clone XMG1.2, BD), an isotype control (clone
A95-1, BD) and anti-human granzyme B (GzB, Caltag) that is
cross-reactive with mouse GzB (Wolint et al., 2004). 100,000–
200,000 cells were analyzed by flow cytometry at the Fox
Chase Cell Sorting Facility using an LSR II system (BD) and
analyzed with FlowJo software.
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